http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2659770-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fda45c540f11df3a7fe71d54a70562a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
filingDate 2007-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d49c4be462b2a7830eb43ddbb8a7ac3
publicationDate 2008-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2659770-A1
titleOfInvention Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
abstract The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5 -inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.
priorityDate 2006-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506981
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743216
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398744
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53630237
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507060
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135413547
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16004692
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135400189
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590271
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480192
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527025
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496402
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506374
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414037530

Total number of triples: 46.